Gut Microbiota And Inflammatory Disorders

Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be involved in immunomodulation as well as inflammation. Prebiotics and probiotics are being explored as therapeutic agents against various inflammatory and autoimmune disorders. Here we discuss the molecular mechanisms involved in gut bacteria-mediated modulation of various inflammatory and autoimmune disorders.PMID:34165407 | DOI:10.2174/1389450122666210623125603
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research